{
  "docId": "019de076-a4b3-719a-94d2-ca29be1b4679",
  "docSlug": "0f14c676100503df3bb87c658cc9d332",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 26,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a process diagram to show the evolution of the FPI-2265 program.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-a4b3-719a-94d2-ca29be1b4679/6",
  "deckHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679",
  "deckJsonHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679.json",
  "deckAnchorHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.32,
        "x": 0.65,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "FPI-2265 Program Evolution: IST study initiation -> Fusion acquired TATCIST -> Fusion aligned with FDA -> Fusion to initiate Phase 2/3 study",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc29e2ee-8ee8-45d7-8445-1bbd34fbe01b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.55,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "list",
      "text": "Expectations for ~25-30 patient Phase 2 data readout: Generally consistent with previously published data; PSA50 response: ~30-50%; Mix of patients who are pre- and post-lutetium, with majority naïve to Pluvicto; Safety profile mostly limited to manageable xerostomia (Grade 1/2) and low rate of high-grade myelotoxicity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ceba0186-f887-4807-9028-6702bc3b08b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.55,
        "x": 0.03,
        "y": 0.58
      },
      "kind": "list",
      "text": "Factors impacting patient response: Number of prior lines of therapies, including 177Lu-PSMA and taxanes; General patient characteristics; e.g. superscan, performance status, liver metastases; PSMA PET uptake (Low PSMA, negative lesions, SUV mean)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff6994d5-62af-4a5c-b80e-551e7fc27ecd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Target Enrollment Complete in TATCIST Study: Data Readout Anticipated in April 2024",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6342c465-1fb8-4fad-977a-ccf098b4c6fb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "8e2905ca-0bf3-4b88-b7d7-9c0982e24d63",
      "evidence": "The FPI-2265 Program Evolution section uses a vertical flow to show sequential steps.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 6,
      "beatId": "6b3d8599-8ead-4bdc-8ad3-1f9f808d7851",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents the solution, including the TATCIST study and Phase 2/3 study initiation",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}